Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for cardiovascular disease
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on cardiovascular disease or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on cardiovascular disease and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via email@example.com
Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovasculardisease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Glucagon-like peptide 1 receptor agonists differ in chemical structure, duration of action, and in their effects on clinical outcomes. The cardiovascular effects of once-weekly albiglutide in type 2 diabetes are unknown. We aimed to determine the safety and efficacy of albiglutide in preventing cardiovascular death (...) , myocardial infarction, or stroke.We did a double-blind, randomised, placebo-controlled trial in 610 sites across 28 countries. We randomly assigned patients aged 40 years and older with type 2 diabetes and cardiovasculardisease (at a 1:1 ratio) to groups that either received a subcutaneous injection of albiglutide (30-50 mg, based on glycaemic response and tolerability) or of a matched volume of placebo once a week, in addition to their standard care. Investigators used an interactive voice or web
2018LancetControlled trial quality: predicted high
Canadian Cardiovascular Harmonized National Guidelines Endeavour (C-CHANGE) guideline for the prevention and management of cardiovasculardisease in primary care Canadian Cardiovascular Harmonized National Guidelines Endeavour (C-CHANGE) guideline for the prevention and management of cardiovasculardisease in primary care: 2018 update | CMAJ Main menu User menu Search Search for this keyword Search for this keyword Guideline Canadian Cardiovascular Harmonized National Guidelines Endeavour (C (...) -CHANGE) guideline for the prevention and management of cardiovasculardisease in primary care: 2018 update Sheldon W. Tobe , James A. Stone , Todd Anderson , Simon Bacon , Alice Y.Y. Cheng , Stella S. Daskalopoulou , Justin A. Ezekowitz , Jean C. Gregoire , Gord Gubitz , Rahul Jain , Karim Keshavjee , Patty Lindsay , Mary L’Abbe , David C.W. Lau , Lawrence A. Leiter , Eileen O’Meara , Glen J. Pearson , Doreen M. Rabi , Diana Sherifali , Peter Selby , Jack V. Tu , Sean Wharton , Kimberly M. Walker
Population surveillance of cardiovasculardiseases in low-income to middle-income countries should leverage existing international collaborations 30294457 2018 11 14 2059-7908 3 5 2018 BMJ global health BMJ Glob Health Population surveillance of cardiovasculardiseases in low-income to middle-income countries should leverage existing international collaborations. e000866 10.1136/bmjgh-2018-000866 Echouffo-Tcheugui Justin B JB Brigham and Women's Hospital, Harvard Medical School, Boston (...) Wales, Sydney, Australia. Non-communicable Diseases Research Unit, South African Medical Research Council & University of Cape Town, Cape Town, South Africa. Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands. eng Journal Article 2018 10 01 England BMJ Glob Health 101685275 2059-7908 control strategies prevention strategies public health Competing interests: None declared. 2018 04 03 2018 08 15 2018 10 9 6 0 2018 10 9 6 0 2018 10 9 6 1
Editorial: Extracellular Vesicle-Mediated Processes in CardiovascularDiseases 30283791 2019 02 02 2297-055X 5 2018 Frontiers in cardiovascular medicine Front Cardiovasc Med Editorial: Extracellular Vesicle-Mediated Processes in CardiovascularDiseases. 133 10.3389/fcvm.2018.00133 Koenen Rory R RR Department of Biochemistry, Cardiovascular Research Institute Maastricht, Maastricht University, Maastricht, Netherlands. Aikawa Elena E Cardiovascular Division, Department of Medicine, Center
Association of dairy intake with cardiovasculardisease and mortality in 21 countries from five continents (PURE): a prospective cohort study. Dietary guidelines recommend minimising consumption of whole-fat dairy products, as they are a source of saturated fats and presumed to adversely affect blood lipids and increase cardiovasculardisease and mortality. Evidence for this contention is sparse and few data for the effects of dairy consumption on health are available from low-income and middle (...) events (deaths [n=6796] or major cardiovascular events [n=5855]) during the 9·1 years of follow-up. Higher intake of total dairy (>2 servings per day compared with no intake) was associated with a lower risk of the composite outcome (HR 0·84, 95% CI 0·75-0·94; ptrend=0·0004), total mortality (0·83, 0·72-0·96; ptrend=0·0052), non-cardiovascular mortality (0·86, 0·72-1·02; ptrend=0·046), cardiovascular mortality (0·77, 0·58-1·01; ptrend=0·029), major cardiovasculardisease (0·78, 0·67-0·90; ptrend=0
, maternal heart disease is the major cause of maternal death during pregnancy. , Hypertensive disorders are the most frequent cardiovasculardisorders during pregnancy, occurring in 5–10% of all pregnancies (see section 10). Among the other diseaseconditions, congenital heart disease is the most frequent CVD present during pregnancy in the western world (75–82%). , Rheumatic valvular disease dominates in non-western countries, comprising 56–89% of all CVDs in pregnancy. , Peripartum intensive care unit (...) for recommending a healthy lifestyle, including smoking cessation. 3.3.1 Risk of maternal cardiovascular complications The risk of complications in pregnancy depends on the underlying cardiac diagnosis, ventricular and valvular function, functional class, presence of cyanosis, pulmonary artery pressures, and other factors. Comorbidities, including for example rheumatoid and musculoskeletal diseases as well as mental disorders, should also be taken into account. Therefore, risk estimation should
Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovasculardisease (ARRIVE): a randomised, double-blind, placebo-controlled trial. The use of aspirin in the primary prevention of cardiovascular events remains controversial. We aimed to assess the efficacy and safety of aspirin versus placebo in patients with a moderate estimated risk of a first cardiovascular event.ARRIVE is a randomised, double-blind, placebo-controlled, multicentre study done (...) in seven countries. Eligible patients were aged 55 years (men) or 60 years (women) and older and had an average cardiovascular risk, deemed to be moderate on the basis of the number of specific risk factors. We excluded patients at high risk of gastrointestinal bleeding or other bleeding, or diabetes. Patients were randomly assigned (1:1) with a computer-generated randomisation code to receive enteric-coated aspirin tablets (100 mg) or placebo tablets, once daily. Patients, investigators, and others
2018LancetControlled trial quality: predicted high
Extracellular Vesicles as Biomarkers in CardiovascularDisease; Chances and Risks The field of extracellular vesicles (EV) is rapidly expanding, also within cardiovasculardiseases. Besides their exciting roles in cell-to-cell communication, EV have the potential to serve as excellent biomarkers, since their counts, content, and origin might provide useful information about the pathophysiology of cardiovasculardisorders. Various studies have already indicated associations of EV counts (...) and content with cardiovasculardiseases. However, EV research is complicated by several factors, most notably the small size of EV. In this review, the advantages and drawbacks of EV-related methods and applications as biomarkers are highlighted.
Excess mortality and cardiovasculardisease in young adults with type 1 diabetes in relation to age at onset: a nationwide, register-based cohort study. People with type 1 diabetes are at elevated risk of mortality and cardiovasculardisease, yet current guidelines do not consider age of onset as an important risk stratifier. We aimed to examine how age at diagnosis of type 1 diabetes relates to excess mortality and cardiovascular risk.We did a nationwide, register-based cohort study (...) of individuals with type 1 diabetes in the Swedish National Diabetes Register and matched controls from the general population. We included patients with at least one registration between Jan 1, 1998, and Dec 31, 2012. Using Cox regression, and with adjustment for diabetes duration, we estimated the excess risk of all-cause mortality, cardiovascular mortality, non-cardiovascular mortality, acute myocardial infarction, stroke, cardiovasculardisease (a composite of acute myocardial infarction and stroke
Urinary sodium excretion, blood pressure, cardiovasculardisease, and mortality: a community-level prospective epidemiological cohort study. WHO recommends that populations consume less than 2 g/day sodium as a preventive measure against cardiovasculardisease, but this target has not been achieved in any country. This recommendation is primarily based on individual-level data from short-term trials of blood pressure (BP) without data relating low sodium intake to reduced cardiovascular events (...) from randomised trials or observational studies. We investigated the associations between community-level mean sodium and potassium intake, cardiovasculardisease, and mortality.The Prospective Urban Rural Epidemiology study is ongoing in 21 countries. Here we report an analysis done in 18 countries with data on clinical outcomes. Eligible participants were adults aged 35-70 years without cardiovasculardisease, sampled from the general population. We used morning fasting urine to estimate 24 h
Disease A Scientific Statement From the American Heart Association Edward P. Havranek , Mahasin S. Mujahid , Donald A. Barr , Irene V. Blair , Meryl S. Cohen , Salvador Cruz-Flores (...) illness and injury at rates that are demonstrably unnecessary.” The report blames many factors, “adverse economic and social conditions” among them. In an editorial in Science discussing the findings of the Institute of Medicine report, Bayer et al call for a national commission on health “to address the social causes (...) supplements, on clinical and selected intermediate cardiovascular (CV) outcomes (i.e., blood pressure, lipid concentrations) and the association of omega-3 FA dietary (...) clinical recommendations or guidelines. Heart and Blood Vessel Conditions Heart Disease Background The first observation of a link between fish consumption and cardiovascular (CV) health was made in the late 1970s in a Greenland Eskimo population. This population exhibited a comparatively low rate of CV mortality and consumed a greater
Development and validation of a cardiovasculardisease risk-prediction model using population health surveys: the CardiovascularDisease Population Risk Tool (CVDPoRT) Routinely collected data from large population health surveys linked to chronic disease outcomes create an opportunity to develop more complex risk-prediction algorithms. We developed a predictive algorithm to estimate 5-year risk of incident cardiovasculardisease in the community setting.We derived the CardiovascularDisease (...) ; women: 0.86, 95% CI 0.85-0.87) and was well-calibrated in the overall population (5-year observed cumulative incidence function v. predicted risk, men: 0.28%; women: 0.38%) and in nearly all predefined policy-relevant subgroups (206 of 208 groups).The CVDPoRT algorithm can accurately discriminate cardiovasculardisease risk for a wide range of health profiles without the aid of clinical measures. Such algorithms hold potential to support precision medicine for individual or population uses. Study
Performance of CardiovascularDisease Risk Scores in People Diagnosed With Type 2 Diabetes: External Validation Using Data From the National Scottish Diabetes Register To evaluate the performance of five cardiovasculardisease (CVD) risk scores developed in diabetes populations and compare their performance to QRISK2.A cohort of people diagnosed with type 2 diabetes between 2004 and 2016 was identified from the Scottish national diabetes register. CVD events were identified using linked (...) hospital and death records. Five-year risk of CVD was estimated using each of QRISK2, ADVANCE (Action in Diabetes and Vascular disease: preterAx and diamicroN-MR Controlled Evaluation), Cardiovascular Health Study (CHS), New Zealand Diabetes Cohort Study (NZ DCS), Fremantle Diabetes Study, and Swedish National Diabetes Register (NDR) risk scores. Discrimination and calibration were assessed using the Harrell C statistic and calibration plots, respectively.The external validation cohort consisted
Skin autofluorescence assessment of cardiovascular risk in people with severe mental illness People with severe mental illness (SMI) show significantly shorter life expectancy, mostly due to more prevalent cardiovasculardisease. Although age is a prominent contributor to contemporary risk assessment and SMI usually affects younger people, these assessments still do not reveal the actual risk. By assessing advanced glycation end products (AGEs), cardiovascular risk can be assessed independent (...) of age.To establish whether detection of AGEs with the AGE-reader will give a more accurate cardiovascular risk assessment in people with SMI.We compared assessment with the AGE-reader with that of the Systematic Coronary Risk Evaluation (SCORE) table in a group of 120 patients with SMI.The AGE-reader showed an increased cardiovascular risk more often than the SCORE table, especially in the youngest group.Because of its ease of use and substantiation by studies done on other chronic diseases, we
Prediction of cardiovasculardisease among hematopoietic cell transplantation survivors Cardiovasculardisease (CVD) is a leading cause of late morbidity and mortality in hematopoietic cell transplantation (HCT) survivors. HCT-specific CVD risk prediction models are needed to facilitate early screening and prevention. In the current study, patients who underwent HCT at City of Hope (COH) and survived 1-year free of clinically evident CVD (N = 1828) were observed for the development of heart (...) failure (HF) or coronary artery disease (CAD) by 10-years from index date (1 year from HCT). CVD occurred in 135 individuals (92 HF, 43 CAD). Risk prediction models were developed for overall CVD (HF and/or CAD) using COH-derived integer risk scores. Risk scores based on selected variables (age, anthracycline dose, chest radiation, hypertension, diabetes, smoking) achieved an area under the curve (AUC) and concordance (C) statistic of 0.74 and 0.72 for CVD; these varied from 0.70 to 0.82 according
Targeting Postprandial Hyperglycemia With Physical Activity May Reduce CardiovascularDisease Risk. But What Should We Do, and When Is the Right Time to Move? Physical inactivity and excessive postprandial hyperglycemia are two major independent risk factors for type 2 diabetes and cardiovascular-related mortality. Current health policy guidelines recommend at least 150 min of physical activity per week coupled with reduced daily sedentary behavior by interrupting prolonged sitting with bouts (...) type 2 diabetes and its cardiovascular complications, this review examines a novel hypothesis that interrupting sitting time would be best focused on the postprandial period in order to optimize blood glucose control and maximize cardiometabolic health. In doing so, we aim to identify the science gaps which urgently need filling if we are to optimize healthcare policy in this critical area.
Omega-6 fats for the primary and secondary prevention of cardiovasculardisease. Omega-6 fats are polyunsaturated fats vital for many physiological functions, but their effect on cardiovasculardisease (CVD) risk is debated.To assess effects of increasing omega-6 fats (linoleic acid (LA), gamma-linolenic acid (GLA), dihomo-gamma-linolenic acid (DGLA) and arachidonic acid (AA)) on CVD and all-cause mortality.We searched CENTRAL, MEDLINE and Embase to May 2017 and clinicaltrials.gov and the World (...) make little or no difference to all-cause mortality (risk ratio (RR) 1.00, 95% confidence interval (CI) 0.88 to 1.12, 740 deaths, 4506 randomised, 10 trials) or CVD events (RR 0.97, 95% CI 0.81 to 1.15, 1404 people experienced events of 4962 randomised, 7 trials). We are uncertain whether increasing omega-6 fats affects CVD mortality (RR 1.09, 95% CI 0.76 to 1.55, 472 deaths, 4019 randomised, 7 trials), coronary heart disease events (RR 0.88, 95% CI 0.66 to 1.17, 1059 people with events of 3997